Market capitalization | $27.92m |
Enterprise Value | $160.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.43 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-26.53m |
Free Cash Flow (TTM) Free Cash Flow | $-19.95m |
Cash position | $27.93m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast NeuroBo Pharmaceuticals Inc:
1 Analyst has issued a forecast NeuroBo Pharmaceuticals Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.02 -0.02 |
-
|
|
EBITDA | -27 -27 |
128%
128%
|
EBIT (Operating Income) EBIT | -27 -27 |
128%
128%
|
Net Profit | -26 -26 |
133%
133%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat neurodegenerative disorders. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
Head office | United States |
CEO | Hyung-Heon Kim |
Employees | 8 |
Founded | 2014 |
Website | www.neurobopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.